MANILA, Philippines — Indian biotechnology company Bharat Biotech has applied for Emergency Use Authorization (EUA) in the country for its COVID-19 vaccine.
The Food and Drug Administration, in a message, has confirmed that Bharat Biotech submitted their application for Covaxin on Wednesday (January 20) and pre-evaluation is already ongoing.
“They submitted an application this morning and pre-evaluation is going on,” according to FDA Director-General Eric Domingo.
Meanwhile, in a statement, the biotech company said that Covaxin is ideal for tropical countries because storage temperature only needs to be set by two to eight degrees celsius.
Bharat Biotech also said the Philippines is among the list of priority countries that will receive Covaxin supply.
“The Philippines is among the list of priority countries that Bharat Biotech will allocate supplies of Covaxin to. It was announced earlier this week that the Indian government has issued a letter of comfort covering this,” the company said in a statement.
Other companies seeking EUA in the country include Astrazeneca, Gamaleya Research Institute, and Sinovac Biotech. -AAC (with reports from Aiko Miguel)
The post India’s Bharat Biotech applies for EUA in Phl for COVID-19 vaccines appeared first on UNTV News.